Article

Micro-thin prescription inserts cleared for keratoconus

The FDA on Aug. 5 approved a Humanitarian Device Exemption (HDE) to Addition Technology Inc. to market its micro-thin prescription inserts (Intacs) for the treatment of keratoconus.

The FDA on Aug. 5 approved a Humanitarian Device Exemption (HDE) to Addition Technology Inc. to market its micro-thin prescription inserts (Intacs) for the treatment of keratoconus.

The FDA based its decision on the safety record of the micro-thin prescription inserts; the relatively low number of U.S. patients (up to 300,000) affected by the disease; and the fact that no other treatment alternative exists for keratoconus patients other than an invasive corneal transplant procedure.

Addition Technology can now market the inserts for the reduction or elimination of myopia and astigmatism in patients with keratoconus.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.